Research programme: hypertension and heart failure therapeutics - Merck/Innoviva
Latest Information Update: 16 Jul 2016
At a glance
- Originator Merck & Co; Theravance
- Developer Innoviva
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure; Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Heart-failure in USA
- 16 Jul 2016 No recent reports of development identified for research development in Hypertension in USA
- 16 Oct 2012 Early research in Heart failure in USA (unspecified route)